Liver Cancer最新文献

{"title":"Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular Carcinoma.","authors":"Jiwon Yang, Won-Mook Choi, Hyung-Don Kim, Jonggi Choi, Changhoon Yoo, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee","doi":"10.1159/000541621","DOIUrl":"https://doi.org/10.1159/000541621","url":null,"abstract":"<p><strong>Introduction: </strong>Proteinuria presents a challenging complication during systemic therapy for hepatocellular carcinoma (HCC). This study aims to identify risk factors for proteinuria in patients with HCC treated with atezolizumab plus bevacizumab (Atezo/Bev) or lenvatinib (LEN) as first-line systemic treatment.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 622 consecutive patients with unresectable HCC who received Atezo/Bev or LEN as first-line systemic treatment between October 2013 and October 2022. Cumulative incidence of proteinuria was estimated using Kaplan-Meier curves and compared using log-rank tests. Risk factors for proteinuria were identified using Cox proportional-hazard models, along with propensity score-matched and subgroup analyses.</p><p><strong>Results: </strong>Among 367 patients treated with Atezo/Bev and 255 with LEN, the cumulative incidence of proteinuria at 12 months was 27.5%. In the multivariable analysis, Atezo/Bev treatment (adjusted HR [aHR]: 1.57; 95% CI: 1.03-2.42), diabetes (aHR: 1.64; 95% CI: 1.03-2.61), hypertension (aHR: 2.27; 95% CI: 1.04-4.97), Child-Pugh class B (aHR: 3.43; 95% CI: 1.34-8.78), macrovascular invasion (MVI; aHR: 1.58; 95% CI: 1.04-2.38), and an estimated glomerular filtration rate ≤60 mL/min/1.73 m² (aHR: 3.21; 95% CI: 1.84-5.62) were identified as risk factors for proteinuria. A higher risk of proteinuria in Atezo/Bev patients compared with LEN was consistently observed in the PS-matched cohort, particularly pronounced in subgroups with MVI (HR: 2.84; 95% CI: 1.23-6.54) compared with those without MVI (HR: 1.31; 95% CI: 0.69-2.47).</p><p><strong>Conclusions: </strong>Patients treated with Atezo/Bev as first-line systemic treatment for HCC exhibited a higher risk of proteinuria compared with those with LEN, particularly when accompanied by MVI.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 2","pages":"180-192"},"PeriodicalIF":11.6,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incorporating ALBI Grade with Geriatric Nutritional Risk Index Enhances Hepatocellular Carcinoma Risk Stratification.","authors":"Heechul Nam, Pil Soo Sung, Sung Won Lee, Do Seon Song, Jung Hyun Kwon, Jeong Won Jang, Chang Wook Kim, Si Hyun Bae","doi":"10.1159/000541647","DOIUrl":"https://doi.org/10.1159/000541647","url":null,"abstract":"<p><strong>Introduction: </strong>Despite its prognostic impact, nutritional status has not yet been integrated into the assessment of hepatocellular carcinoma (HCC). This study investigated the association between geriatric nutritional risk index (GNRI) and overall survival (OS) in patients with HCC using a nationwide registry.</p><p><strong>Methods: </strong>Data from the Korea Central Cancer Registry between 2008 and 2019 were analyzed. We explored the integration of the GNRI with the albumin-bilirubin (ALBI) grade for prognostic stratification. Restricted cubic spline regression was used to assess the association between GNRI and survival, stratified by ALBI grade.</p><p><strong>Results: </strong>Among the 16,416 treatment-naïve HCC patients, the ALBI grades were distributed as follows: grade 1, 7,409; grade 2, 7,445; and grade 3, 1,562. Patients were categorized according to Barcelona Clinic Liver Cancer (BCLC) stages: 5,132 stage 0/A, 2,608 stage B, 5,289 stage C, and 968 stage D. The median OS for all patients was 3.1 years (95% CI: 3.0-3.2) and significantly differed with the inclusion of ALBI grade and GNRI (<i>p</i> < 0.001). The effect of combining ALBI grade and GNRI was further evaluated for each BCLC stage. This risk stratification showed a significant correlation with OS for each BCLC stage (all <i>p</i> < 0.001), except for stage D (<i>p</i> = 0.082). Multivariate analysis revealed that a combination of favorable ALBI grade and high GNRI score was independently associated with decreased mortality risk.</p><p><strong>Conclusion: </strong>The GNRI was significantly correlated with OS across ALBI grades and BCLC stages. Integrating the GNRI into the ALBI grade may enhance risk stratification for patients with HCC.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 2","pages":"193-210"},"PeriodicalIF":11.6,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Radiation Dose and Tumour Burden on Outcomes in Hepatocellular Carcinoma: 11-Year Experience in a 413-Patient Cohort Treated with Yttrium-90 Resin Microsphere Radioembolisation.","authors":"Kaina Chen, Aaron K T Tong, Fiona N N Moe, David C E Ng, Richard H G Lo, Apoorva Gogna, Sean X Yan, Sue Ping Thang, Kelvin S H Loke, Nanda Karaddi Venkatanarasimha, Hian Liang Huang, Chow Wei Too, Timothy S K Ong, Eng Xuan Yeo, Daniel Yang Yao Peh, Ashley W Y Ng, Lu Yang, Wan Ying Chan, Jason P E Chang, Brian K P Goh, Han Chong Toh, Pierce K H Chow","doi":"10.1159/000541539","DOIUrl":"https://doi.org/10.1159/000541539","url":null,"abstract":"<p><strong>Introduction: </strong>Transarterial radioembolisation (RE) using yttrium-90 (Y-90) microspheres is a widely used locoregional therapy for a broad spectrum of hepatocellular carcinoma (HCC) given its favourable safety profile. We evaluated the real-world outcomes of unresectable HCC treated with resin Y-90 RE and the relationship between tumour absorbed dose and subsequent curative therapy with survival.</p><p><strong>Methods: </strong>Included were consecutive patients treated with Y-90 resin microspheres RE for unresectable HCC between January 2008 and May 2019 at the National Cancer Centre Singapore/Singapore General Hospital. The outcomes were stratified by tumour burden, distribution, presence of portal vein invasion (PVI) and liver function to improve prognostication.</p><p><strong>Results: </strong>The median overall survival (OS) evaluated on 413 included patients was 20.9 months (95% CI: 18.2-24.0). More than half of the patients (214/413, 51.8%) had HCC beyond up-to-seven criteria, and 37.3% had portal vein invasion (154/413, 37.3%). Majority (71.7%) had dosimetry calculated based on the partition model. Patients who received ≥150 Gy to tumour had significantly better outcomes (OS 32.2 months, 95% CI: 18.3-46.4) than those who did not (OS 17.5 months, 95% CI: 13.7-22.7, <i>p</i> < 0.001). Seventy patients (17%) received curative therapies after tumour was downstaged by Y-90 RE and had better OS of 79.7 months (95% CI: 40.4 - NE) compared to those who did not receive curative therapies (OS 17.1 months; 95% CI: 13.5-20.4, <i>p</i> < 0.001). RE-induced liver injury was observed in 5.08% of the patients while 3.2% of the patients had possible radiation pneumonitis but none developed Grade 3-4 toxicity. For HCC without PVI, OS differed significantly with performance status, albumin-bilirubin grade, tumour distribution, and radiation dose; for HCC with PVI, Child-Pugh class and AFP were significant predictors of survival.</p><p><strong>Conclusions: </strong>Treatment outcomes for unresectable HCC using Y-90 RE were favourable. Incorporating tumour burden and distribution improved prognostication. Patients who received tumour absorbed dose above 150 Gy had better OS. Patients who subsequently received curative therapies after being downstaged by Y-90 RE had remarkable clinical outcomes.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 2","pages":"158-179"},"PeriodicalIF":11.6,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Depth of Radiographic Response as an Independent Prognostic Factor for Patients with Initially Unresectable Hepatocellular Carcinoma Receiving Hepatectomy following Targeted Therapy plus Immunotherapy.","authors":"Bin Xu, Lu-Na Wang, Zi-Yi Wang, Tian He, Xiao-Dong Zhu, Ying-Hao Shen, Jian Zhou, Jia Fan, Hui-Chuan Sun, Cheng Huang","doi":"10.1159/000541300","DOIUrl":"https://doi.org/10.1159/000541300","url":null,"abstract":"<p><strong>Introduction: </strong>Surgical resection following systemic therapy is feasible in patients with initially unresectable hepatocellular carcinoma (HCC). However, postoperative tumor recurrence is common after surgery, and the factors affecting this recurrence remain unclear. This study aimed to assess factors influencing postoperative outcomes in patients with initially unresectable HCC undergoing hepatectomy after systemic therapy.</p><p><strong>Methods: </strong>This study retrospectively enrolled patients with initially unresectable HCC who underwent hepatectomy after targeted therapy plus immunotherapy (with or without locoregional therapy). Multivariate Cox regression analyses were used to identify the independent prognostic factors for recurrence-free survival (RFS) and overall survival (OS). Machine learning was used to determine the RFS rates at different intervals for different radiographic responses.</p><p><strong>Results: </strong>Eighty-one patients who underwent R0 hepatectomy after systemic therapy were included. With a median follow-up of 17.4 (interquartile range: 7.2-22.3) months, median RFS and OS were not reached. Preoperative tumor downstaging and achieving pathological complete response were associated with improved RFS and OS. Multivariate Cox analyses identified radiographic response as an independent prognostic factor for RFS and OS. Furthermore, a radiographic response >40% (assessed using the Response Evaluation Criteria in Solid Tumors, version 1.1) or >50% (assessed using the modified Response Evaluation Criteria in Solid Tumors) was associated with a longer RFS (<i>p</i> = 0.006 and 0.003, respectively).</p><p><strong>Conclusion: </strong>Radiographic response depth was an independent prognostic factor in patients with initially unresectable HCC who underwent hepatectomy following targeted therapy plus immunotherapy, and the response to systemic therapy may be the determining factor for patient prognosis after surgery.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 2","pages":"142-157"},"PeriodicalIF":11.6,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update.","authors":"Xinyu Bi, Haitao Zhao, Hong Zhao, Guangming Li, Xiaodong Wang, Bo Chen, Wen Zhang, Xu Che, Zhen Huang, Yue Han, Liming Jiang, Yongkun Sun, Zhengqiang Yang, Jianguo Zhou, Yefan Zhang, Zhenyu Zhu, Minshan Chen, Shuqun Cheng, Jianqiang Cai","doi":"10.1159/000541249","DOIUrl":"https://doi.org/10.1159/000541249","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a common malignancy in China, with high recurrence rate and low resection rate among patients first diagnosed. Preoperative treatments including neoadjuvant and conversion therapy have the potential to overcome these challenges. In December 2021, <i>Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma</i> was published. With the emersion of new evidence regarding the neoadjuvant and conversion therapies for HCC, the cooperative group brought together multidisciplinary researchers and scholars with experience in related fields to update the new edition (2023 Edition) for reference in China, including principle of the treatment strategies, the potential populations selection, treatment methods, multidisciplinary team, and future research for preoperative treatments. The new consensus aims to provide guidance for clinical application. Through the use of neoadjuvant therapy and conversion therapy, we can enhance the resection rate and reduce the recurrence of intermediate-to-advanced HCC patients, thereby improving survival outcomes.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 2","pages":"223-238"},"PeriodicalIF":11.6,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic Peripheral T-Cell Analysis Identifies On-Treatment Prognostic Biomarkers of Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma.","authors":"Ji Won Han, Min Woo Kang, Soon Kyu Lee, Hyun Yang, Ji Hoon Kim, Jae-Sung Yoo, Hee Sun Cho, Eun Ji Jang, Deok Hwa Seo, Jung Hyun Kwon, Soon Woo Nam, Si Hyun Bae, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung","doi":"10.1159/000541181","DOIUrl":"10.1159/000541181","url":null,"abstract":"<p><strong>Introduction: </strong>Variability in response to atezolizumab plus bevacizumab (AB) treatment of hepatocellular carcinoma (HCC) underscores the critical need for the development of effective biomarkers. We sought to identify peripheral blood biomarkers reflecting response to AB treatment.</p><p><strong>Methods: </strong>We analyzed dynamic changes in peripheral blood mononuclear cells from a prospective, multicenter cohort of 65 patients with HCC, using flow cytometry to evaluate the T-cell population before and 3 weeks after the first AB treatment.</p><p><strong>Results: </strong>We found a unique response of the CD8⁺ T cells in terms of both frequency and phenotype, in contrast to CD4⁺ T cells and regulatory T cells. Notably, CD8⁺ T cells showed significant changes in expression of Ki-67 and T-cell immunoreceptors with Ig and ITIM domains (TIGIT). These distinct responses were observed particularly in the programmed cell death receptor-1 (PD-1)⁺ subpopulation of CD8⁺ T cells. Interestingly, the baseline differentiation status of PD-1⁺CD8⁺ T cells, particularly the central memory T-cell subset, correlated positively with greater proliferation (higher Ki-67 expression) of PD-1⁺CD8⁺ T cells after treatment. Moreover, effector memory cells expressing CD45RA correlated negatively with the increase in TIGIT⁺/PD-1⁺CD8⁺ T cells. The increase in TIGIT⁺/CD8⁺ T cells was associated with the development of immune-related adverse events, whereas increase in Ki-67⁺/PD-1⁺CD8⁺ T cells was associated with the better objective response rate. Importantly, dynamic shifts of Ki-67⁺/PD-1⁺CD8⁺ T cells and TIGIT⁺/CD8⁺ T cells significantly predicted progression-free survival and overall survival, as confirmed by multivariate analysis.</p><p><strong>Conclusion: </strong>These findings highlight the potential of dynamic changes in CD8⁺ T cells as an on-treatment prognostic biomarker. Our study underscores the value of peripheral blood profiling as a noninvasive and practical method for predicting the clinical outcomes of AB treatment in patients with HCC.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 1","pages":"104-116"},"PeriodicalIF":11.6,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11936438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143719828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Particle Therapy for Intrahepatic Cholangiocarcinoma: A Multicenter Prospective Registry Study, Systematic Review and Meta-Analysis.","authors":"Masashi Mizumoto, Kei Shibuya, Kazuki Terashima, Masao Murakami, Motohiro Murakami, Yoshiyuki Shioyama, Yoshiro Matsuo, Takashi Ogino, Tatsuya Ohno, Takahiro Waki, Hiroyuki Ogino, Hiroyasu Tamamura, Norio Katoh, Masaru Wakatsuki, Tomoaki Okimoto, Motohisa Suzuki, Takashi Saito, Shingo Toyama, Takayuki Hashimoto, Hisateru Ohba, Shoji Kubo, Kiyoshi Hasegawa, Kazushi Maruo, Hideyuki Sakurai","doi":"10.1159/000540291","DOIUrl":"https://doi.org/10.1159/000540291","url":null,"abstract":"<p><strong>Introduction: </strong>A prospective study was started in May 2016 to evaluate the efficacy and safety of particle therapy for intrahepatic cholangial carcinoma (ICC). To compare treatment modalities, we also conducted a meta-analysis of literature data and a systematic comparison using registry data.</p><p><strong>Methods: </strong>Patients who received particle therapy for ICC from May 2016 to June 2018 were registered. Nineteen manuscripts (4 particle therapy, 8 3D-CRT, 7 SBRT) were selected for the meta-analysis.</p><p><strong>Results: </strong>A total of 85 cases (proton beam therapy 59, carbon therapy 26) were registered. The median overall survival (OS) of the 85 patients was 22.1 months (95% CI: 12.9-31.3); the 1-, 2-, 3-, and 4-year OS rates were 70.9% (95% CI: 61.1-80.7%), 47.6% (36.8-58.4%), 37.7% (26.7-48.7%), and 22.7% (10.2-35.2%), respectively; and the 1-, 2-, 3-, and 4-year local recurrence rates were 8.2% (1.1-15.3%), 21.6% (9.3-33.9%), 33.4% (16.7-50.1%), and 33.4% (16.7-50.1%), respectively. In the meta-analysis and registry data, the 1-year OS for particle therapy, SBRT and 3D-CRT were 71.8% (95% CI: 64.6-77.8%), 59.2% (53.0-64.9%, <i>p</i> = 0.0573), and 47.2% (36.8-56.9%, <i>p</i> = 0.0004), respectively. The incidence of grade 3 or higher late non-hematological toxicity in the meta-analysis and registry data were 7.4-12% for particle therapy, 6.7-16.7% for SBRT, and 8.1-14.3% for 3D-CRT.</p><p><strong>Conclusions: </strong>Particle therapy achieved a good therapeutic effect for ICC, and a meta-analysis indicated that particle therapy is a better treatment modality than SBRT and 3D-CRT.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 2","pages":"211-222"},"PeriodicalIF":11.6,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144064171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Normal Hepatobiliary Cell Zonation Programs on the Phenotypes and Functions of Primary Liver Tumors.","authors":"Tomoko Aoki, Naoshi Nishida, Yasunori Minami, Masatoshi Kudo","doi":"10.1159/000541077","DOIUrl":"10.1159/000541077","url":null,"abstract":"<p><strong>Background: </strong>Traditional tumor classifications have relied on cellular origin, pathological morphological features, gene expression profiles, and more recently, the tumor immune microenvironment. While these classifications provide valuable insights, incorporating physiological classifications focusing on liver metabolic functions may lead to new discoveries.</p><p><strong>Summary: </strong>We proposed to reclassify benign and malignant hepatocellular neoplasms based on their physiological functions such as albumin production, bile acid production, glycolysis, glycogenesis, and adipogenesis. We further demonstrated the homology between signal pathways activated by the differentiation program of the normal hepatobiliary cells and those activated by genetic abnormalities in tumors. Specifically, Wnt/β-catenin, RAS, NOTCH, and TGF-β signaling not only contribute to cell differentiation via activation of liver-enriched transcription factors but also determine the tumor traits. Examining the distinctions between hepatocellular carcinomas (HCCs) that maintain or lose metabolic functions can yield valuable insights into the drivers of biological malignancy and tumor plasticity.</p><p><strong>Key messages: </strong>To confirm the homology between the differentiation programs of normal hepatobiliary cells, hepatocellular adenomas (HCA), and HCC we identify liver-specific functions such as catabolism and anabolism within tumors. HCCs and HCAs that have lost these metabolic functions exhibit characteristics such as dedifferentiation, resemblance to biliary cells, or increased glycolysis. Focusing on this underexplored area will likely stimulate active research into new tumor characteristics.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 1","pages":"92-103"},"PeriodicalIF":11.6,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11936443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143719962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Diabetes Mellitus and Obesity Comorbidities on Survival Outcomes after Hepatocellular Carcinoma Resection: A Multicenter Retrospective Study.","authors":"Hiroji Shinkawa, Masaki Kaibori, Masaki Ueno, Satoshi Yasuda, Hisashi Ikoma, Tsukasa Aihara, Takuya Nakai, Masahiko Kinoshita, Hisashi Kosaka, Shinya Hayami, Yasuko Matsuo, Ryo Morimura, Takayoshi Nakajima, Chihoko Nobori, Takeaki Ishizawa","doi":"10.1159/000540858","DOIUrl":"10.1159/000540858","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to evaluate the association of obesity and diabetes mellitus (DM) comorbidity with hepatocellular carcinoma (HCC) recurrence and survival.</p><p><strong>Methods: </strong>We investigated 1,644 patients who underwent hepatic resection for solitary HCC without vascular invasion using computed tomography. Patients were categorized into four groups according to the combination of obesity and DM comorbidities: OB (+) or (-) and DM (+) or (-). Postoperative cumulative recurrence rates within and beyond 2 years and beyond 5 years were assessed.</p><p><strong>Results: </strong>Multivariate Cox proportional hazard regression analysis revealed that the adjusted hazard ratios (HRs) of reduced recurrence-free survival was 1.10 (95% confidence interval [CI]: 0.91-1.33; <i>p</i> = 0.31), 0.94 (95% CI: 0.78-1.12; <i>p</i> = 0.48), and 1.24 (95% CI: 1.01-1.54; <i>p</i> = 0.045) in the OB(+)DM(-), OB(-)DM(+), and OB(+)DM(+) groups compared with the OB(-)DM(-) group, respectively. Additionally, the corresponding adjusted HRs of reduced overall survival were 0.93 (<i>p</i> = 0.57), 0.97 (<i>p</i> = 0.76), and 1.38 (<i>p</i> = 0.013) for OB(+)DM(-), OB(-)DM(+), and OB(+)DM(+) groups, respectively. No significant difference in the early recurrence rate was determined among the four groups. The OB(+)DM(+) group demonstrated an increased risk for late recurrence beyond 2 years and 5 years postoperatively compared with the OB(-)DM(-) group (HR: 1.51; <i>p</i> = 0.024 and HR: 2.53; <i>p</i> = 0.046, respectively). The OB(+)DM(-) and OB(-)DM(+) groups demonstrated an increased risk for late recurrence beyond 5 years postoperatively (HR: 3.83; <i>p</i> < 0.001 and HR: 1.95; <i>p</i> = 0.037, respectively).</p><p><strong>Conclusions: </strong>Obesity and DM coexistence increased late recurrence and worsened prognosis in patients with HCC undergoing hepatic resection. The results help surgeons develop possible different surveillance protocol and need to focus on diabetes/obesity control during life-long surveillance for patients with HCC.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 1","pages":"80-91"},"PeriodicalIF":11.6,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11936440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143719862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries.","authors":"Choong-Kun Lee, Changhoon Yoo, Jung Yong Hong, Se Jun Park, Jin Won Kim, David Wai Meng Tai, Hyeyeong Kim, Krittiya Korphaisarn, Suebpong Tanasanvimon, San-Chi Chen, Ju Won Kim, Ilhwan Kim, Moonho Kim, Joan Choo, Sang-Bo Oh, Ching-Tso Chen, Woo Kyun Bae, Hongsik Kim, Seok Jae Huh, Chia-Jui Yen, Sejung Park, Dong Ki Lee, Landon Long Chan, Beodeul Kang, Minsu Kang, Raghav Sundar, Hye Jin Choi, Stephen Lam Chan, Hong Jae Chon, Myung-Ah Lee","doi":"10.1159/000540969","DOIUrl":"https://doi.org/10.1159/000540969","url":null,"abstract":"<p><strong>Introduction: </strong>Atezolizumab plus bevacizumab is a commonly used first-line regimen for advanced hepatocellular carcinoma (HCC) treatment owing to its superior outcomes compared to sorafenib. However, optimal subsequent treatment options for patients with HCC who progressed on first-line atezolizumab plus bevacizumab remain unclear.</p><p><strong>Methods: </strong>This multinational, multi-institutional, retrospective study included patients with HCC from 22 centers in five Asia-Pacific countries who were treated with first-line atezolizumab plus bevacizumab, which was discontinued for any reason. The endpoints included progression-free survival (PFS) and overall survival (OS) according to patient characteristics and second-line regimens.</p><p><strong>Results: </strong>Between June 2016 and May 2023, 1,141 patients were treated with first-line atezolizumab plus bevacizumab, of whom 629 (55.1%) received subsequent treatment. Sorafenib and lenvatinib were the most commonly administered second-line regimens (53.9% and 25.6%, respectively). Overall, the median PFS and OS were 2.9 and 8.0 months, respectively. Lenvatinib had longer PFS (4.0 vs. 2.3 months) and OS (8.0 vs. 6.3 months) than sorafenib. Patients treated with tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI) (<i>n</i> = 50, 8.3%) showed PFS and OS of 5.4 and 12.6 months, respectively. Lower tumor burden and lenvatinib or TKI plus ICI use were associated with longer second-line PFS. Preserved liver function was associated with improved OS.</p><p><strong>Conclusions: </strong>In patients with HCC who progressed on first-line atezolizumab plus bevacizumab, sorafenib and lenvatinib were the most commonly used second-line regimens in Asia-Pacific countries, with lenvatinib resulting in longer OS than sorafenib. The second-line TKI plus ICI combination exhibited promising efficacy, suggesting the potential role of continuing ICIs beyond disease progression.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 2","pages":"127-141"},"PeriodicalIF":11.6,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}